# BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect

> **NCT03212586** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 72 (actual)

## Conditions studied

- Clinical Trials, Phase I as Topic

## Interventions

- **DRUG:** BAY1902607
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03212586
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-18
- **Primary completion:** 2018-05-03
- **Final completion:** 2018-07-27
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2019-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03212586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03212586, "BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03212586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*